Search Results for: Pharma: Clinical Roundup
-
miRagen Moves to Next Level with $20M Series B
The company has near-future plans to conduct a preclinical study of MGN 4893 (targeted to miR 451) in polycythemia vera that will determine a route forward for the compound and the timing of initiation of clinical studies...Rodman & Renshaw LLC acted as exclusive placement agent.By Catherine Shaffer | BioWorld Today | Wednesday, April 25, 2012 -
Clinic Roundup
Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.SBioWorld Today | Tuesday, April 10, 2012 -
Pharma: Clinic Roundup
CSL Behring is developing rVIIa-FP as a treatment for hemophilia A and hemophilia B patients who have inhibitors as part of the PROLONG 7- FP clinical study programBioWorld Today | Monday, April 2, 2012 -
Satori Raises $15M for AD Platform, Looks to File IND
Serendipitously, independent clinical studies of the antecedent biomarkers of AD seem to have corroborated Satori's approach, he addedBy Marie Powers | BioWorld Today | Friday, February 24, 2012 -
Clinic Roundup
The project, "Human genetics-driven discovery of memory-modulating drugs," will start in March and will include three clinical studies supported by a CTI grant for three years...Niiki Pharma Inc., of Hoboken, N.J., said it completed the dose-escalation portion of its Phase I trial of NKP-1339, a small molecule designed to down-regulate GRP78, a tumor survival and anti-apoptosis factorBioWorld Today | Wednesday, January 18, 2012 -
Clinic Roundup
Radius Health Inc., of Cambridge, Mass., reported that its transdermal BA058 microneedle patch, for osteoporosis, showed positive results in a Phase Ib clinical study...UCB Pharma SA, of Brussels, Belgium, began a trial (EXXELERATE) of Cimzia (certolizumab pegol) plus methotrexate compared with Humira (adalimumab) plus methotrexate for rheumatoid arthritisBioWorld Today | Thursday, December 22, 2011 -
YM Reports Phase I/II Success In Myelofibrosis; Shares Rise
It's a great fit with clinical need and best suited to deal with the three major factors associated with myelofibrosis...Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported clinical data from a number of programs...Astellas Pharma Inc., of Tokyo, and Ambit Biosciences Corp., of San Diego, shared updated results from an interim analysis of a Phase II trial of quizartinib (previously AC220) in acute myeloid leukemia, showing that quizartinib monotherapy had activity in refractory and relapsedBy Catherine Shaffer | BioWorld Today | Wednesday, December 14, 2011 -
Clinic Roundup
Bellicum Pharmaceuticals Inc., of Houston, reported that the results of the first clinical study of its CaspaCIDe technology showed that it worked quickly and effectively without compromising the function of the cell and may have broad application as a safety feature for cell therapy...Clinical follow-up, completed three months after the administration of PLX-PAD cells, noted statistically significant improvements in several parameters, including ankle-brachial index (p = 0.033), transcutaneousBioWorld Today | Friday, November 4, 2011 -
Tensha Bags $15M Financing For Bromodomain Inhibitors
The financing will allow Tensha to advance its lead program through clinical proof of concept, lay the groundwork for clinical studies in other cancer indications and advance the preclinical development of bromodomain inhibitors in areas outside of oncology, according to Onsi, who declined to speculate on a timetable for any investigational new drug filingsBy Marie Powers | BioWorld Today | Tuesday, September 13, 2011 -
Pulmatrix Hastens COPD Trials Via $14M Series B1 Financing
The lead liquid formulation, PUR003, previously had shown safety and tolerability in patients with asthma and influenza, and, with the latest funding in hand, the firm plans to launch five clinical studies of dry powder candidate PUR118, starting with two Phase Ib trials in COPD...In COPD, the company will need some big pharma muscleBy Jennifer Boggs | BioWorld Today | Tuesday, August 16, 2011 -
Lotus Gets $26M Series A: Skin Disease, Wound Healing
For now the company's scientific founders, David Woodley and Mei Chen at USC, have just received a National Institutes of Health grant for a clinical study of the recombinant protein in epidermolysis bullosa patients...A.P. Pharma Inc., of Redwood City, Calif., entered a definitive agreement with new and existing investors to raise $24 million in a private placement of common stock and warrantsBy Anette Breindl | BioWorld Today | Thursday, June 30, 2011 -
Tesaro Scores Biggest 2011 VC Round with $101M Series B
OncoSec said it intends to use proceeds from the offering for further development of its ElectroOncology therapies to treat cancers, for clinical studies and for general corporate purposes.By Tom Wall | BioWorld Today | Wednesday, June 22, 2011 -
Clinic Roundup
Adeona Pharmaceuticals Inc., of Ann Arbor, Mich., announced that analyses of a clinical study evaluating reaZin, a gastroretentive, sustained-release, once-daily oral tablet formulated from zinc (150 mg) and amino acid cysteine (100 mg) for treatment of Alzheimer's disease, indicated that the older the reaZin treatment patient, the greater the amount of cognitive benefit compared to the placebo patients of the same age...NovaDel Pharma Inc., of Bridgewater, N.J., opened an investigational new drugBioWorld Today | Friday, June 3, 2011 -
GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress
We have a network of pharma experts who all told us, if it was their compound it would be given the green light to go into clinical development...The company said it will use the funds to complete Phase IIa studies with lead Smac mimetic drug candidate, TL32711, in solid tumors and to initiate clinical studies in hematological cancers.By Nuala Moran | BioWorld Today | Wednesday, May 25, 2011 -
Clinic Roundup
Meritage Pharma Inc., of San Diego, said a Phase IIb trial of oral budesonide suspension for eosinophilic esophagitis met its primary endpoin...The proposed revision would permit participants to receive either docetaxel re-treatment or cabazitaxel as chemotherapy in the clinical studyBioWorld Today | Wednesday, May 11, 2011 -
Financings Roundup
A.P. Pharma Inc., of Redwood City, Calif., will raise $4.5 million in convertible notes in a private placement deal with certain investors, including Tang Capital Partners...The discussion topics included dosing system, clarification of assays for manufacture and quality control, and a QT/metabolism clinical studyBioWorld Today | Tuesday, April 26, 2011 -
Merrimack Pharmaceuticals' Series G Brings in $77M
Under the agreement, GTC would receive an initial inventory of bulk drug substance for use in clinical studies...Merrimack's first major pharma deal, in 2009, focused on MM-121By Catherine Shaffer | BioWorld Today | Monday, April 18, 2011 -
Public Offering to Net a Cool $40M for ArQule
The two companies share equally the cost of Phase II and Phase III clinical studies...ArQule's clinical pipeline additionally includes ARQ 621, an Eg5 inhibitor, in Phase I and ARQ 736, a pan-RAF inhibitorBy Catherine Shaffer | BioWorld Today | Friday, January 21, 2011 -
NovImmune Tops Off Licensing Deal with $20.6 M
Clinical studies are slated to start in early 2011By Catherine Shaffer | BioWorld Today | Monday, December 20, 2010 -
XenoPort Prices Public Offering of 4M Shares
The Horizant NDA resubmission also included a final safety update, which provided updated and new safety information on patients in clinical studies who have been treated with the drug...Geron said it plans to use the net proceeds for R&D, including clinical trials for its product candidates, development activities for in-licensed products and other general corporate purposesBy Donna Young | BioWorld Today | Friday, December 10, 2010
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.